Biochemical markers identify influences on bone and cartilage degradation in osteoarthritis--the effect of sex, Kellgren-Lawrence (KL) score, body mass index (BMI), oral salmon calcitonin (sCT) treatment and diurnal variation

What Was Tested

This randomized controlled trial paper looks at Calcitonin in the context of osteoarthritis, cartilage loss & avoiding joint replacement.

Osteoarthritis (OA) involves changes in both bone and cartilage.

These processes might be associated under some circumstances.

Who Took Part

The abstract describes 37 women taking part.

By PubMed's age tags, the people studied were middle-aged adults and older adults, both men and women.

This study was a 2-week, double-blind, double-dummy, randomized study including 37 postmenopausal women and 36 men, aged 57-75 years, with painful knee OA, and a KL-score of I - III.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

The women were allocated by chance, so the Calcitonin group and the comparison group should start out alike.

Neither the women nor the staff measuring them knew who was on Calcitonin, so expectations could not easily colour the readings.

A placebo (an inactive look-alike) gave the Calcitonin group a baseline to be compared against.

Correlations between gender, KL score, or BMI and the bone resorption marker, serum C-terminal telopeptide of collagen type I (CTX-I), or the cartilage degradation marker, urine C-terminal telopeptide of collagen type II (CTX-II) were investigated.

What Was Measured

This study investigated correlations between bone and cartilage degradation in patients with OA as a function of sex, Kellgren-Lawrence (KL) score, Body Mass Index (BMI), oral salmon calcitonin (sCT) treatment and diurnal variation.

The subject headings attached to it are Biomarkers, Body Mass Index, Bone Density, Bone and Bones, Calcitonin, Cartilage, Articular and Circadian Rhythm.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Calcitonin in 37 women in people with osteoarthritis, cartilage loss & avoiding joint replacement.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 11 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2010 (BMC musculoskeletal disorders), a journal based in England.

More context: the Calcitonin compound page, Osteoarthritis, cartilage loss & avoiding joint replacement research.